Ionis EVP exercises 1,680 options, sells shares at $75.054 avg

Q: What did IONIS EVP Richard S. Geary report on Form 4/A?

An amended Form 4 correcting amounts. On 11/03/2025 he exercised options for 775 and 905 shares and sold the same counts.

Q: At what prices were the IONS option exercises and sales recorded?

Exercises occurred at $60.89 (775 shares) and $56.78 (905 shares). Sales used a $75.054 weighted average, ranging $75.00–$75.25.

Q: How many IONS shares did Richard S. Geary own after the transactions?

He beneficially owned 59,657 common shares directly after the reported transactions.

Q: What was corrected in this IONS Form 4/A filing?

The amendment corrects the amount of shares acquired or disposed of reported in Column 4.

Q: Were the IONS sales executed in multiple trades?

Yes. The price is a weighted average; trades occurred between $75.00 and $75.25 inclusive.

Q: What roles does the reporting person hold at IONS?

Richard S. Geary is EVP, Chief Development Officer at Ionis Pharmaceuticals.

Ionis Pharmaceuticals (IONS) executive Richard S. Geary filed an amended Form 4 to correct share amounts.

Accepted by SEC EDGAR 11/07/2025 - 05:12 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) executive Richard S. Geary filed an amended Form 4 to correct share amounts. On 11/03/2025, he exercised stock options for 775 shares at $60.89 and 905 shares at $56.78, then sold 775 and 905 common shares at a $75.054 weighted average price, with trades ranging from $75.00 to $75.25.

Following these transactions, Geary beneficially owned 59,657 common shares directly. The amendment states it corrects the amounts reported in Column 4.

Insider Trade Summary

Exercise and Sale: 1,680 shares ($28K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Geary Richard S

Role EVP, Chief Development Officer

Sold 1,680 shs ($126K)

Approx. gross sale proceeds $126K

Approx. exercise cost $99K

Approx. pre-tax spread $28K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right to buy)	905	$0.00	$0.00
Exercise	Non-Qualified Stock Option (right to buy)	775	$0.00	$0.00
Exercise	Common Stock	775	$60.89	$47K
Sale	Common Stock	775	$75.054	$58K
Exercise	Common Stock	905	$56.78	$51K
Sale	Common Stock	905	$75.054	$68K

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 34,639 contracts (Direct); Common Stock — 59,657 shares (Direct)

Footnotes (2)

F1. This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IONIS EVP Richard S. Geary report on Form 4/A?

An amended Form 4 correcting amounts. On 11/03/2025 he exercised options for 775 and 905 shares and sold the same counts.

At what prices were the IONS option exercises and sales recorded?

Exercises occurred at $60.89 (775 shares) and $56.78 (905 shares). Sales used a $75.054 weighted average, ranging $75.00–$75.25.

How many IONS shares did Richard S. Geary own after the transactions?

He beneficially owned 59,657 common shares directly after the reported transactions.

What was corrected in this IONS Form 4/A filing?

The amendment corrects the amount of shares acquired or disposed of reported in Column 4.

Were the IONS sales executed in multiple trades?

Yes. The price is a weighted average; trades occurred between $75.00 and $75.25 inclusive.

What roles does the reporting person hold at IONS?

Richard S. Geary is EVP, Chief Development Officer at Ionis Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Geary Richard S

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/03/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/03/2025		M		775⁽¹⁾	A	$60.89	60,432	D
Common Stock	11/03/2025		S		775⁽¹⁾	D	$75.054⁽²⁾	59,657	D
Common Stock	11/03/2025		M		905⁽¹⁾	A	$56.78	60,562	D
Common Stock	11/03/2025		S		905⁽¹⁾	D	$75.054⁽²⁾	59,657	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right to buy)	$56.78	11/03/2025		M			905⁽¹⁾	01/02/2023	01/03/2028	Common Stock	905	$0.0	15,538	D
Non-Qualified Stock Option (right to buy)	$60.89	11/03/2025		M			775⁽¹⁾	01/04/2024	01/01/2027	Common Stock	775	$0.0	19,101	D

Explanation of Responses:

1. This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

	By: Patrick R. O'Neil, attorney-in-fact For: Richard S. Geary	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR